Researchers developed a sustained-release microsphere formulation of NMN that significantly alleviates chemotherapy-induced myelosuppression by restoring bone marrow function and peripheral blood cell counts in animal models. The mechanism involves activation of the PI3K-PTEN-AKT-Bcl-2 signaling pathway, which protects hematopoietic stem cells from chemotherapy-induced apoptosis and promotes cytokine secretion. This formulation approach addresses a major clinical problem in cancer patients—bone marrow suppression—and represents a promising therapeutic strategy for chemotherapy side-effect management.
For your business
NMN depot microspheres restored marrow function in chemotherapy models via AKT-Bcl-2 HSC protection — warrants monitoring in oncology support contexts.